A new study from Karolinska Institutet, published in Cell Reports Medicine, shows that follicular lymphoma (FL), a common ...

The collaboration will fund early-stage clinical development of SB-4826, CIT’s first-in-class SUMO E1 inhibitor, for patients ...

Epcoritamab shows promising results in treating relapsed follicular lymphoma, with FDA priority review for a groundbreaking ...

Results from the Phase III EPCORE FL-1 trial (NCT05409066) showed that patients treated with Epkinly (epcoritamab) in ...

Genmab has announced that its phase 3 EPCORE FL-1 trial met both primary endpoints in patients with relapsed or refractory ...

A new study from Karolinska Institutet, published in Cell Reports Medicine, shows that follicular lymphoma (FL), a common ...

Follicular lymphoma survivor Troy Anderson credited acupuncture and nutrition guidance with easing treatment side effects and ...

Epkinly with Rituxan and Revlimid, compared to Rituxan and Revlimid alone, reduced risk of progression or death by 79%.

Christina Poh, MD, of City of Hope National Medical Center, highlights the benefit of tafasitamab in improving progression-free survival for heavily pretreated patients with relapsed or refractory ...

The Food and Drug Administration (FDA) has issued another Complete Response Letter (CRL) to Regeneron (CRL) for the Biologics License Application (BLA) for odronextamab in relapsed/refractory ...

Bristol Myers Squibb (BMS) has announced that its CD19-directed CAR T cell therapy Breyanzi (lisocabtagene maraleucel) has ...

Company Announcement COPENHAGEN, Denmark; August 7, 2025 Epcoritamab in combination with rituximab and lenalidomide (R2) demonstrated statistically significant improvement in Overall Response Rate ...